Structured Colon Cancer Exercise Trials Show Lower Recurrence Rates
Structured exercise programs can keep certain cancers at bay and cut healthcare costs, yet these initiatives remain largely unfunded and inaccessible to the general public, according to reporting by Nina Agrawal in the New York Times. A major randomized trial focused on colon cancer found that patients who participated in supervised exercise over a three-year period experienced a lower likelihood of cancer recurrence. Those participants demonstrated a higher probability of being alive eight years later.
The supervised exercise program carries a price tag of about $3,000 per person. Despite this upfront cost, the intervention ultimately saved the healthcare system money.
Insurance Coverage for Exercise Oncology Lacks, Leaving Patients to Rely on Philanthropy
Insurers mostly decline to pay for exercise oncology, forcing patients to rely on philanthropy, hospital pilots, or community programs like the YMCA. Cancer patients are routinely counseled on chemotherapy and scans during clinical visits, while physical workouts receive barely a mention from care teams.
One notable exception is set to launch next year at the University of Pittsburgh Medical Center. The architect of the initiative describes the coverage launch as a giant experiment that could potentially help turn structured physical activity from a casual suggestion into standard cancer care.
Frequently Asked Questions About Cancer Exercise Trials
How much does the supervised exercise program cost per patient?
The structured exercise program evaluated in the colon cancer trial costs about $3,000 per person.
Which healthcare system is starting to cover exercise programs for breast cancer patients?
The University of Pittsburgh Medical Center is launching coverage for a tailored exercise program through its employee health plan.
What were the long-term survival findings from the colon cancer study?
Patients who completed the three-year supervised exercise regimen were less likely to see their cancer return and showed a higher likelihood of being alive eight years later.
Related reading